Just over a week ago, some 40,000 oncology professionals from across the globe gathered in Chicago, USA, for the exchange and debate of the very latest clinical cancer research at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May – 04 June. Themed Caring for Every Patient, Learning from Every Patient, several of our clinical investigators were on the ground throughout the course of the meeting to present studies they have either led or have collaborated in as co-authors.
In addition to our recent news coverage of just some of these studies (see: Headlining at ASCO’s 2019 Annual Meeting: VHIO driving advances against gastrointestinal tumors, and A hand-pick of additional highlights on the ground last week at ASCO 2019), specialized international media including The ASCO Post and oncology channel ecancer, invited selected VHIO faculty to comment on their respective studies, including the following interviews captured on film (click on the respective images to access each video):
The ASCO Post Newsreels‘ interview with our Director, Josep Tabernero on the findings he presented from the Phase III KEYNOTE-062 study: Pembrolizumab with or without chemotherapy for advanced gastric of gastroesophageal junction adenocarcinoma.
In an ecancer interview, Josep Tabernero also discussed the results from KEYNOTE-062 and the use of immunotherapy agent pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers.
ecancer also caught up with both Enriqueta Felip, PI of our Thoracic Tumors & Head and Neck Cancer Group, and Teresa Macarulla, PI of VHIO’s Gastrointestinal & Endocrine Tumors Group, for comment on their respective research as follows:
Enriqueta Felip spoke to ecancer about the preliminary results from a phase II study examining the combination of bemcentinib and pembrolizumab in patients with advanced NSCLC.
Teresa Macarulla discussed findings from the phase III POLO trial – which assessed the use of olaparib as a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA1/2 mutation and metastatic pancreatic cancer, compared with a placebo.
In the company of Neal Shore, Carolina Rologic Research Center (South Carolina, USA), and Karim Fizazi, Insttut Gustave Roussy (Paris, France), Joaquim Mateo participated in an ecancer Expert Discussion focused on the treatment and management of metastatic castration resistant prostate cancer (mCRPC).
The panel discuss the TOPARP-B results presented at ASCO 2019 as well as ongoing studies ARAMIS and VISION, and Joaquin offers his advice regarding managing patients treated with PARPi.
###
